File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

TitlePredicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
Authors
Issue Date2007
PublisherB M J Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
Citation
Gut, 2007, v. 56 n. 5, p. 699-705 How to Cite?
Abstract
OBJECTIVE: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of pre-treatment factors on post-treatment responses was investigated. METHODS: Multivariate analyses were performed using available data from 518 patients treated with peginterferon alpha-2a with or without lamivudine, or with lamivudine alone. A post-treatment response was defined as alanine aminotransferase (ALT) normalisation and hepatitis B virus (HBV) DNA level of <20,000 copies/ml. RESULTS: In logistic regression analyses across all treatment arms, peginterferon alpha-2a (with or without lamivudine) therapy, younger age, female gender, high baseline ALT, low baseline HBV DNA and HBV genotype were identified as significant predictors of combined response at 24 weeks post-treatment. In the peginterferon alpha-2a and lamivudine monotherapy arms, patients with genotypes B or C had a higher chance of response than genotype D infected patients (p<0.001), the latter responding better to the combination than to peginterferon alpha-2a monotherapy (p = 0.015). At 1 year post-treatment, response rates by intention-to-treat analysis were 19.2% for the peginterferon alpha-2a, 19.0% for the combination, and 10.0% for the lamivudine groups, with genotypes B or C associated with a sustained combined response to peginterferon alpha-2a with or without lamivudine therapy. CONCLUSIONS: Baseline ALT and HBV DNA levels, patient age, gender, and infecting HBV genotype significantly influenced combined response at 24 weeks post-treatment, in patients treated with peginterferon alpha-2a and/or lamivudine. At 1 year post-treatment HBV genotype was significantly predictive of efficacy for patients treated with peginterferon alpha-2a with or without lamivudine.
Persistent Identifierhttp://hdl.handle.net/10722/57523
ISSN
2013 Impact Factor: 13.319
PubMed Central ID
ISI Accession Number ID

 

Author Affiliations
  1. F. Hoffmann-La Roche AG
  2. Papageorgiou General Hospital
  3. Prince of Songkla University
  4. The University of Hong Kong
  5. Beijing Youan Hospital
  6. Ankara Üniversitesi
  7. Hospital General Universitario de Valencia
  8. Roche
  9. Università di Pisa
  10. National Taiwan University Hospital
  11. Azienda Ospedaliera-Universitaria Pisana
  12. IRCCS Foundation Rome
  13. Università degli Studi di Cagliari
  14. Henry Dunant Hospital
  15. Hopital Beaujon
  16. Uludağ Üniversitesi
DC FieldValueLanguage
dc.contributor.authorBonino, Fen_HK
dc.contributor.authorMarcellin, Pen_HK
dc.contributor.authorLau, GKKen_HK
dc.contributor.authorHadziyannis, Sen_HK
dc.contributor.authorJin, Ren_HK
dc.contributor.authorPiratvisuth, Ten_HK
dc.contributor.authorGermanidis, Gen_HK
dc.contributor.authorYurdaydin, Cen_HK
dc.contributor.authorDiago, Men_HK
dc.contributor.authorGurel, Sen_HK
dc.contributor.authorLai, MYen_HK
dc.contributor.authorBrunetto, MRen_HK
dc.contributor.authorFarci, Pen_HK
dc.contributor.authorPopescu, Men_HK
dc.contributor.authorMcCloud, Pen_HK
dc.date.accessioned2010-04-12T01:39:05Z-
dc.date.available2010-04-12T01:39:05Z-
dc.date.issued2007en_HK
dc.identifier.citationGut, 2007, v. 56 n. 5, p. 699-705en_HK
dc.identifier.issn0017-5749en_HK
dc.identifier.urihttp://hdl.handle.net/10722/57523-
dc.description.abstractOBJECTIVE: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of pre-treatment factors on post-treatment responses was investigated. METHODS: Multivariate analyses were performed using available data from 518 patients treated with peginterferon alpha-2a with or without lamivudine, or with lamivudine alone. A post-treatment response was defined as alanine aminotransferase (ALT) normalisation and hepatitis B virus (HBV) DNA level of <20,000 copies/ml. RESULTS: In logistic regression analyses across all treatment arms, peginterferon alpha-2a (with or without lamivudine) therapy, younger age, female gender, high baseline ALT, low baseline HBV DNA and HBV genotype were identified as significant predictors of combined response at 24 weeks post-treatment. In the peginterferon alpha-2a and lamivudine monotherapy arms, patients with genotypes B or C had a higher chance of response than genotype D infected patients (p<0.001), the latter responding better to the combination than to peginterferon alpha-2a monotherapy (p = 0.015). At 1 year post-treatment, response rates by intention-to-treat analysis were 19.2% for the peginterferon alpha-2a, 19.0% for the combination, and 10.0% for the lamivudine groups, with genotypes B or C associated with a sustained combined response to peginterferon alpha-2a with or without lamivudine therapy. CONCLUSIONS: Baseline ALT and HBV DNA levels, patient age, gender, and infecting HBV genotype significantly influenced combined response at 24 weeks post-treatment, in patients treated with peginterferon alpha-2a and/or lamivudine. At 1 year post-treatment HBV genotype was significantly predictive of efficacy for patients treated with peginterferon alpha-2a with or without lamivudine.en_HK
dc.languageengen_HK
dc.publisherB M J Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/en_HK
dc.rightsGut. Copyright © B M J Publishing Group.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshHepatitis B, Chronic - drug therapy - virologyen_HK
dc.subject.meshInterferon Alfa-2a - therapeutic useen_HK
dc.subject.meshPolyethylene Glycols - therapeutic useen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.titlePredicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis Ben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0017-5749&volume=56&issue=5&spage=699&epage=705&date=2007&atitle=Predicting+response+to+peginterferon+α-2a,+lamivudine+and+the+two+combined+for+HBeAg-negative+chronic+hepatitis+Ben_HK
dc.identifier.emailBonino, F: bonino@med-club.comen_HK
dc.identifier.emailLau, GKK: gkklau@netvigator.comen_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1136/gut.2005.089722en_HK
dc.identifier.pmid17127704en_HK
dc.identifier.pmcidPMC1942152-
dc.identifier.scopuseid_2-s2.0-34247538953-
dc.identifier.isiWOS:000245780200020-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats